Gilead Sciences, Inc.
NEWS
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
The most recent figure for the China coronavirus outbreak is 28,018 confirmed cases with 563 deaths in China. Chinese health authorities indicate 19 foreigners have been infected by the virus. There are reports that a Chinese newborn is the youngest person to become infected. The infant was diagnosed 30 hours after birth, apparently having gotten it from the mother.
The Wuhan Institute of Virology, part of the China Academy of Sciences, has applied to patent the use of Gilead Sciences’ remdesivir to treat the current coronavirus outbreak.
Gilead Sciences is boosting support for a Bay Area startup looking to develop a new class of therapies for autoimmune diseases.
The State of California is considering a measure to sell its own brand of generic drugs in an effort to get in on those cost-savings. California’s Gov. Gavin Newsom is expected to reveal the scheme today in his new state budget.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
According to an analysis conducted on Jan. 1, more than 250 drugs manufactured by different companies saw price increases.
BMS accused Kite and Gilead of copying the research conducted at Memorial Sloan Kettering to push the development of Yescarta.
Earlier this week, an HIV-prevention advocacy group, PrEP4All Collaboration, filed a petition with the U.S. Patent and Trademark Office (PTO) alleging that Gilead Sciences intentionally delayed the development of a safer HIV drug.
JOBS
IN THE PRESS